No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab

Abstract

We concluded that extending the NZ dosing interval did not increase axonal damage, as determined with sNfL, in patients with RRMS.